Hib-DTP-hepatitis B-poliovirus vaccine (Easysix) - Panacea Biotec

Drug Profile

Hib-DTP-hepatitis B-poliovirus vaccine (Easysix) - Panacea Biotec

Alternative Names: Easysix; Fully liquid hexavalent DTwP-HepB-Hib-IPV vaccine - Panacea Biotec; Temperature-stable vaccine (Hib-DTP-hepatitis B-poliovirus vaccine) - Panacea Biotec

Latest Information Update: 08 Sep 2016

Price : $50

At a glance

  • Originator Panacea Biotec
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 02 Sep 2016 Panacea Biotech plans a phase II/III trial Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus infections and Poliomyelitis (In infants, Prevention) in India (CTRI2015-02-005578)
  • 22 Dec 2010 Panacea Biotec completes a phase I trial of Easysix™ in healthy infants aged 15-18 months for Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus infections and Poliomyelitis in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top